A multivariate analysis performed to determine predictors of overall mortality identified nodal status of the primary, number of metastases and completeness of hepatic resection (R0 versus R1/R2) as the only independent predictors of mortality. After a mean follow-up of 70 thenthereby months for all patients,

135/219 patients developed recurrent disease. Recurrent liver-only disease developed in 49 patients, and Inhibitors,research,lifescience,medical 12 patients developed both intra- and extrahepatic recurrence. The site(s) of recurrence did not differ between the resection groups. Given the impact of the entire extent of disease burden on oncologic outcomes, the case-matched study by Moug et al. (19) of 32 patients who underwent simultaneous versus staged resections is particularly informative Inhibitors,research,lifescience,medical regarding oncologic click here outcomes following these two resection

approaches. As noted above, the patients in this study were matched for age, gender, American Society of Anesthesiologists grade, type of hepatic and colon resection. The overall median survival in the synchronous resection group was 39 months and compared favorably with the median survival of 42 months observed in the staged resection group. Similarly, the median time to cancer recurrence in the synchronous resection Inhibitors,research,lifescience,medical group was 10 months, similar to the 14 month disease-free survival seen among the staged resection patients. Although the small sample size is a limitation of Inhibitors,research,lifescience,medical this study, these findings provide some provisional evidence that timing of resection does not appear to impact oncologic outcomes adversely. As discussed previously, the group from M.D. Anderson Cancer Center has recently

published their experience with the “Reverse Strategy” toward staged Inhibitors,research,lifescience,medical resection of synchronous colorectal hepatic metastases (5). In their study, they reported an overall median survival for the entire population who underwent complete resection of all disease of 64 months. Median survival rates were 95 months in the simultaneous resection group, 55 months in the classic resection group, and Drug_discovery 50 months in the “Reverse Strategy” resection group. Overall, 65% of all patients developed recurrent disease: 53% in the combined resection group, 71% in the classic resection group, and 70% in the “Reverse Strategy” group. These recurrence rates were not significantly different. Additionally, median disease-free survivals were the same in the three groups. The authors noted that the outcomes for patients treated with the “Reverse Strategy” who had more extensive disease were similar to outcomes of patients treated with the classic or simultaneous resection groups who had a smaller overall disease burden. In summary, oncologic outcomes are superior following complete resection of all disease when compared to best available systemic therapies.